Long-term efficacy of rituximab in hepatitis C virus-associated cryoglobulinemia

Página do item simplificado
dc.contributor.authorPereira, Patrícia da Silva Fucuta [UNIFESP]
dc.contributor.authorLemos, Lara Barros [UNIFESP]
dc.contributor.authorOliveira Uehara, Silvia Naomi de [UNIFESP]
dc.contributor.authorSouza e Silva, Ivonete Sandra de [UNIFESP]
dc.contributor.authorBenedito Silva, Antonio Eduardo [UNIFESP]
dc.contributor.authorFerraz, Maria Lucia Cardoso Gomes [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:05:24Z
dc.date.available2016-01-24T14:05:24Z
dc.date.issued2010-09-01
dc.description.abstractMixed cryoglobulinemia is one of the most closely related extrahepatic manifestations of hepatitis C virus and requires a challenging therapeutic approach depending on the severity of the symptoms. Here, we describe the long-term follow-up of a patient with important cutaneous, articular and neural manifestations of cryoglobulinemia associated with chronic hepatitis C treated with rituximab. A 42-year-old woman who did not respond to previous interferon-based treatments (standard and pegylated interferon plus ribavirin) and corticosteroids was subjected to treatment with rituximab at a dose of 375 mg/mA(2) per week for 4 consecutive weeks. the drug was well tolerated and complete improvement of arthralgia was immediately evident. There was gradual improvement of lower limbs paresthesia and healing of a leg ulcer that had been active for 5 years. the clinical and immunological responses induced by rituximab are sustained over long-term follow-up, and this case illustrates the drug efficacy for non-responder patients to antiviral therapy.en
dc.description.affiliationUniversidade Federal de São Paulo, Div Gastroenterol, Hepatitis Sect, BR-04023900 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Gastroenterol, Hepatitis Sect, BR-04023900 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1515-1518
dc.identifierhttp://dx.doi.org/10.1007/s00296-009-1106-1
dc.identifier.citationRheumatology International. Heidelberg: Springer Heidelberg, v. 30, n. 11, p. 1515-1518, 2010.
dc.identifier.doi10.1007/s00296-009-1106-1
dc.identifier.issn0172-8172
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/32864
dc.identifier.wosWOS:000281254400019
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofRheumatology International
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectCryoglobulinemiaen
dc.subjectHepatitis C virusen
dc.subjectRituximaben
dc.subjectVasculitisen
dc.titleLong-term efficacy of rituximab in hepatitis C virus-associated cryoglobulinemiaen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral